Top

Published in:

Open Access 01-12-2014 | Review

Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells

Authors: Ammad Ahmad Farooqi, Ming-Feng Hou, Chien-Chi Chen, Chun-Lin Wang, Hsueh-Wei Chang

Published in: Cancer Cell International | Issue 1/2014

Abstract

Prostate cancer is a gland tumor in the male reproductive system. It is a multifaceted and genomically complex disease. Transmembrane protease, serine 2 and v-ets erythroblastosis virus E26 homolog (TMPRSS2-ERG) gene fusions are the common molecular signature of prostate cancer. Although tremendous advances have been made in unraveling various facets of TMPRSS2-ERG-positive prostate cancer, many research findings must be sequentially collected and re-interpreted. It is important to understand the activation or repression of target genes and proteins in response to various stimuli and the assembly in signal transduction in TMPRSS2-ERG fusion-positive prostate cancer cells. Accordingly, we divide this multi-component review ofprostate cancer cells into several segments: 1) The role of TMPRSS2-ERG fusion in genomic instability and methylated regulation in prostate cancer and normal cells; 2) Signal transduction cascades in TMPRSS2-ERG fusion-positive prostate cancer; 3) Overexpressed genes in TMPRSS2-ERG fusion-positive prostate cancer cells; 4) miRNA mediated regulation of the androgen receptor (AR) and its associated protein network; 5) Quantitative control of ERG in prostate cancer cells; 6) TMPRSS2-ERG encoded protein targeting; In conclusion, we provide a detailed understanding of TMPRSS2-ERG fusion related information in prostate cancer development to provide a rationale for exploring TMPRSS2-ERG fusion-mediated molecular network machinery.

Ribarska T, Bastian KM, Koch A, Schulz WA: Specific changes in the expression of imprinted genes in prostate cancer–implications for cancer progression and epigenetic regulation. Asian J Androl. 2012, 14 (3): 436-450.PubMedCentralPubMed

Kumar-Sinha C, Tomlins SA, Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008, 8 (7): 497-511.PubMedCentralPubMed

Chiu YT, Liu J, Tang K, Wong YC, Khanna KK, Ling MT: Inactivation of ATM/ATR DNA damage checkpoint promotes androgen induced chromosomal instability in prostate epithelial cells. PLoS One. 2012, 7 (12): e51108-PubMedCentralPubMed

Bonaccorsi L, Nesi G, Nuti F, Paglierani M, Krausz C, Masieri L, Serni S, Proietti-Pannunzi L, Fang Y, Jhanwar SC, Orlando C, Carini M, Forti G, Baldi E, Luzzatto L: Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results. J Endocrinol Invest. 2009, 32 (7): 590-596.PubMed

Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG: Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell. 2009, 139 (6): 1069-1083.PubMedCentralPubMed

Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S: Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010, 42 (8): 668-675.PubMedCentralPubMed

Rubin MA: ETS rearrangements in prostate cancer. Asian J Androl. 2012, 14 (3): 393-399.PubMedCentralPubMed

Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Rossi AR, Vicari L, Liso V, Rocchi M, Specchia G: Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Mol Cancer. 2010, 9: 120-PubMedCentralPubMed

Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng FY: Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia. 2013, 15 (10): 1207-1217.PubMedCentralPubMed

10.

Narod SA, Seth A, Nam R: Fusion in the ETS gene family and prostate cancer. Br J Cancer. 2008, 99 (6): 847-851.PubMedCentralPubMed

11.

Shah RB, Chinnaiyan AM: The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Adv Anat Pathol. 2009, 16 (3): 145-153.PubMed

12.

Clark JP, Cooper CS: ETS gene fusions in prostate cancer. Nat Rev Urol. 2009, 6 (8): 429-439.PubMed

13.

FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG: Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008, 8: 230-PubMedCentralPubMed

14.

Turner NC, Reis-Filho JS: Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012, 13 (4): e178-185.PubMed

15.

Lee AJ, Swanton C: Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics. Biochem Pharmacol. 2012, 83 (8): 1013-1020.PubMed

16.

Gerlinger M, Swanton C: How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010, 103 (8): 1139-1143.PubMedCentralPubMed

17.

Marusyk A, Almendro V, Polyak K: Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer. 2012, 12 (5): 323-334.PubMed

18.

Brabletz T: To differentiate or not–routes towards metastasis. Nat Rev Cancer. 2012, 12 (6): 425-436.PubMed

19.

Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles R, Martin FL, Phillips DH, Crundwell M, Christmas T, Thompson A, Fisher C, Kovacs G, Cooper CS: Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007, 26 (18): 2667-2673.PubMed

20.

Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Rohr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sultmann H, Lehrach H, Schweiger MR: Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2012, 2 (11): 1024-1035.PubMed

21.

Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S, Hube-Magg C, Prien K, Pham T, Weigand P, Michl U, Heinzer H, Kluth M, Minner S, Tsourlakis MC, Izbicki JR, Sauter G, Schlomm T, Wilczak W: SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate. 2013, 73 (15): 1690-1698.PubMed

22.

Sirma H, Broemel M, Stumm L, Tsourlakis T, Steurer S, Tennstedt P, Salomon G, Michl U, Haese A, Simon R, Sauter G, Schlomm T, Minner S: Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncol Lett. 2013, 6 (5): 1245-1252.PubMedCentralPubMed

23.

Stumm L, Burkhardt L, Steurer S, Simon R, Adam M, Becker A, Sauter G, Minner S, Schlomm T, Sirma H, Michl U: Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. J Clin Pathol. 2013, 66 (7): 563-568.PubMed

24.

Grupp K, Boumesli R, Tsourlakis MC, Koop C, Wilczak W, Adam M, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A: Int J Cancer. 2014

25.

Fodde R, Smits R, Clevers H: APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001, 1 (1): 55-67.PubMed

26.

Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J, Zarour L, Higano C, True LD, Vessella RL, Wilmot B, Bottomly D, McWeeney SK, Bova GS, Partin AW, Mori M, Alumkal J: A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics. 2011, 6 (10): 1248-1256.PubMedCentralPubMed

27.

Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, Cao X, Lonigro RJ, Tomlins SA, Varambally S, Chinnaiyan AM: TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res. 2011, 71 (16): 5387-5392.PubMedCentralPubMed

28.

Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schroder FH, Wildhagen MF, van Leenders GJ: ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol. 2012, 25 (3): 471-479.PubMed

29.

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM: An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010, 17 (5): 443-454.PubMedCentralPubMed

30.

Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC, Oliver RT, Berney DM, Lu YJ: Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res. 2010, 70 (23): 9544-9548.PubMedCentralPubMed

31.

Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J: TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006, 66 (22): 10658-10663.PubMed

32.

Lehmusvaara S, Erkkila T, Urbanucci A, Waltering K, Seppala J, Larjo A, Tuominen VJ, Isola J, Kujala P, Lahdesmaki H, Kaipia A, Tammela T, Visakorpi T: Chemical castration and anti-androgens induce differential gene expression in prostate cancer. J Pathol. 2012, 227 (3): 336-345.PubMed

33.

Ateeq B, Vellaichamy A, Tomlins SA, Wang R, Cao Q, Lonigro RJ, Pienta KJ, Varambally S: Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. Prostate. 2012, 72 (14): 1542-1549.PubMed

34.

Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H, Sauter G, Simon R, Schlomm T, Beissbarth T, Korf U, Kuner R, Sultmann H: TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer. 2011, 11: 507-PubMedCentralPubMed

35.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL: Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010, 18 (1): 11-22.PubMedCentralPubMed

36.

Mao X, Boyd LK, Yanez-Munoz RJ, Chaplin T, Xue L, Lin D, Shan L, Berney DM, Young BD, Lu YJ: Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am J Cancer Res. 2011, 1 (5): 604-617.PubMedCentralPubMed

37.

Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger HA, Brase JC, Kuner R, Schlomm T, Sauter G, Sultmann H, Korf U, Bokemeyer C, Walther R, Brummendorf TH, Balabanov S: Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res. 2012, 11 (4): 2452-2466.PubMed

38.

Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM: Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011, 19 (5): 664-678.PubMedCentralPubMed

39.

Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, Mucci LA, Giovannucci E: Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011, 29 (17): 2378-2385.PubMedCentralPubMed

40.

Washington MN, Weigel NL: 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology. 2010, 151 (4): 1409-1417.PubMedCentralPubMed

41.

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R: TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011, 6 (7): e21650-PubMedCentralPubMed

42.

Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ: Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev. 2011, 25 (20): 2147-2157.PubMedCentralPubMed

43.

Hollenhorst PC: RAS/ERK pathway transcriptional regulation through ETS/AP-1 binding sites. Small GTPases. 2012, 3 (3): 154-158.PubMedCentralPubMed

44.

Yin L, Rao P, Elson P, Wang J, Ittmann M, Heston WD: Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS One. 2011, 6 (6): e21319-PubMedCentralPubMed

45.

Li Y, Kong D, Wang Z, Ahmad A, Bao B, Padhye S, Sarkar FH: Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. Cancer Prev Res (Phila). 2011, 4 (9): 1495-1506.

46.

Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O: TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006, 66 (21): 10242-10246.PubMed

47.

Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O: FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2010, 70 (17): 6735-6745.PubMed

48.

Nhili R, Peixoto P, Depauw S, Flajollet S, Dezitter X, Munde MM, Ismail MA, Kumar A, Farahat AA, Stephens CE, Duterque-Coquillaud M, David Wilson W, Boykin DW, David-Cordonnier MH: Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Res. 2013, 41 (1): 125-138.PubMedCentralPubMed

49.

Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F: ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia. 2010, 12 (12): 1031-1040.PubMedCentralPubMed

50.

Kubosaki A, Tomaru Y, Tagami M, Arner E, Miura H, Suzuki T, Suzuki M, Suzuki H, Hayashizaki Y: Genome-wide investigation of in vivo EGR-1 binding sites in monocytic differentiation. Genome Biol. 2009, 10 (4): R41-PubMedCentralPubMed

51.

Vitari AC, Leong KG, Newton K, Yee C, O'Rourke K, Liu J, Phu L, Vij R, Ferrando R, Couto SS, Mohan S, Pandita A, Hongo JA, Arnott D, Wertz IE, Gao WQ, French DM, Dixit VM: COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature. 2011, 474 (7351): 403-406.PubMed

52.

Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Perner S, Wernert N: The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?. Mol Med Rep. 2012, 5 (2): 313-316.PubMed

53.

Ribeiro FR, Paulo P, Costa VL, Barros-Silva JD, Ramalho-Carvalho J, Jeronimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, Teixeira MR: Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One. 2011, 6 (7): e22317-PubMedCentralPubMed

54.

Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C: ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells. PLoS One. 2011, 6 (11): e28162-PubMedCentralPubMed

55.

Flajollet S, Tian TV, Flourens A, Tomavo N, Villers A, Bonnelye E, Aubert S, Leroy X, Duterque-Coquillaud M: Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin. Mol Cancer Res. 2011, 9 (7): 914-924.PubMed

56.

Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jeronimo C, Sveen A, Mills IG, Skotheim RI, Lothe RA, Teixeira MR: Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia. 2012, 14 (7): 600-611.PubMedCentralPubMed

57.

Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G, Ittmann M: Activation of NF-{kappa}B by TMPRSS2/ERG fusion isoforms through toll-like receptor-4. Cancer Res. 2011, 71 (4): 1325-1333.PubMedCentralPubMed

58.

Becker-Santos DD, Guo Y, Ghaffari M, Vickers ED, Lehman M, Altamirano-Dimas M, Oloumi A, Furukawa J, Sharma M, Wang Y, Dedhar S, Cox ME: Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis. 2012, 33 (12): 2558-2567.PubMedCentralPubMed

59.

Muller J, Ehlers A, Burkhardt L, Sirma H, Steuber T, Graefen M, Sauter G, Minner S, Simon R, Schlomm T, Michl U: Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer. 2013, 132 (6): 1333-1340.PubMed

60.

Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G: Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis. 2010, 13 (4): 311-315.PubMed

61.

Chow A, Amemiya Y, Sugar L, Nam R, Seth A: Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer. Anticancer Res. 2012, 32 (9): 3629-3641.PubMed

62.

Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X: ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013, 123 (3): 1109-1122.PubMedCentralPubMed

63.

Kacprzyk LA, Laible M, Andrasiuk T, Brase JC, Borno ST, Falth M, Kuner R, Lehrach H, Schweiger MR, Sultmann H: ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer. PLoS One. 2013, 8 (3): e59976-PubMedCentralPubMed

64.

Chinni S, Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W, Cher ML: Transcriptional regulation of CXCR4 in prostate tumor cells: Significance of TMPRSS2-ERG fusions. Mol Cancer Res. 2013, in press [PMID: 23918819]

65.

Tian TV, Tomavo N, Huot L, Flourens A, Bonnelye E, Flajollet S, Hot D, Leroy X, de Launoit Y, Duterque-Coquillaud M: Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene. 2013, in press [PMID: 23708657]

66.

Chen R, Zeng X, Zhang R, Huang J, Kuang X, Yang J, Liu J, Tawfik O, Brantley Thrasher J, Li B: Ca1.3 channel alpha protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol Oncol. 2013, in press [PMID: 24054868]

67.

Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004, 10 (1): 33-39.PubMed

68.

Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE: miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69 (18): 7165-7169.PubMedCentralPubMed

69.

Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ: miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem. 2009, 284 (37): 24696-24704.PubMedCentralPubMed

70.

Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS, Petrovics G, Awwad HO, Ward Y, Lake R, Zhang L, Kelly K: TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS One. 2012, 7 (7): e41668-PubMedCentralPubMed

71.

Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M: Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006, 66 (11): 5723-5728.PubMed

72.

Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP: Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res. 2009, 69 (12): 5202-5209.PubMed

73.

Pignon JC, Koopmansch B, Nolens G, Delacroix L, Waltregny D, Winkler R: Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res. 2009, 69 (7): 2941-2949.PubMed

74.

Hsu FN, Yang MS, Lin E, Tseng CF, Lin H: The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells. Am J Physiol Endocrinol Metab. 2011, 300 (5): E902-908.PubMed

75.

Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004, 6 (5): 517-527.PubMed

76.

Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS: Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res. 2005, 11 (5): 1704-1712.PubMed

77.

Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS, Whang YE: Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 2005, 65 (8): 3404-3409.PubMed

78.

Epis MR, Barker A, Giles KM, Beveridge DJ, Leedman PJ: The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem. 2011, 286 (48): 41442-41454.PubMedCentralPubMed

79.

Yeap BB, Voon DC, Vivian JP, McCulloch RK, Thomson AM, Giles KM, Czyzyk-Krzeska MF, Furneaux H, Wilce MC, Wilce JA, Leedman PJ: Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3'-untranslated region of the androgen receptor messenger RNA. J Biol Chem. 2002, 277 (30): 27183-27192.PubMed

80.

Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M: MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate. 2010, 70 (14): 1501-1512.PubMed

81.

Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Deng G, Dahiya R: MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One. 2012, 7 (1): e29722-PubMedCentralPubMed

82.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009, 41 (5): 619-624.PubMedCentralPubMed

83.

Cai J, Kandagatla P, Singareddy R, Kropinski A, Sheng S, Cher ML, Chinni SR: Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells. Transl Oncol. 2010, 3 (3): 195-203.PubMedCentralPubMed

84.

Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, Zhao J, Meng YL, Ren XL, Wang T, Li Q, Jin BQ, Yao LB, Wang RA, Fan DM, Chen SY, Jia LT, Yang AG: HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology. 2011, 141 (6): 2076-2087. e2076PubMed

85.

de Muga S, Hernandez S, Salido M, Lorenzo M, Agell L, Juanpere N, Lorente JA, Serrano S, Lloreta J: CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement. Cancer Biomark. 2012, 12 (1): 21-30.PubMed

86.

Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL: Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. Hum Mol Genet. 2012, 21 (14): 3112-3127.PubMed

87.

Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC: miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer. 2011, 129 (4): 810-819.PubMed

88.

Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC: MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012, 287 (2): 1527-1537.PubMedCentralPubMed

89.

Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin C, Zhang W: microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep. 2012, 27 (6): 1967-1975.PubMed

90.

Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn F, Hackermuller J: MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 2013, 32 (3): 277-285.PubMed

91.

Li Y, Kong D, Ahmad A, Bao B, Dyson G, Sarkar FH: Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. Epigenetics. 2012, 7 (8): 940-949.PubMedCentralPubMed

92.

Miyajima N, Maruyama S, Bohgaki M, Kano S, Shigemura M, Shinohara N, Nonomura K, Hatakeyama S: TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. Cancer Res. 2008, 68 (9): 3486-3494.PubMed

93.

Barboro P, Repaci E, Ferrari N, Rubagotti A, Boccardo F, Balbi C: Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. Prostate. 2011, 71 (13): 1466-1479.PubMed

94.

Mukhopadhyay NK, Kim J, Cinar B, Ramachandran A, Hager MH, Di Vizio D, Adam RM, Rubin MA, Raychaudhuri P, De Benedetti A, Freeman MR: Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res. 2009, 69 (6): 2210-2218.PubMedCentralPubMed

95.

Szczyrba J, Nolte E, Hart M, Doll C, Wach S, Taubert H, Keck B, Kremmer E, Stohr R, Hartmann A, Wieland W, Wullich B, Grasser FA: Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. Int J Cancer. 2013, 132 (4): 775-784.PubMed

96.

Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I, Zaman MS, Deng G, Tanaka Y, Dahiya R: miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res. 2012, 72 (14): 3618-3630.PubMed

97.

Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY, Yan M: microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep. 2012, 27 (4): 1019-1026.PubMedCentralPubMed

98.

Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z, Chun-Sheng K: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010, 10: 367-PubMedCentralPubMed

99.

Fu X, Tian J, Zhang L, Chen Y, Hao Q: Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 2012, 586 (9): 1279-1286.PubMed

100.

Fornari F, Milazzo M, Chieco P, Negrini M, Marasco E, Capranico G, Mantovani V, Marinello J, Sabbioni S, Callegari E, Cescon M, Ravaioli M, Croce CM, Bolondi L, Gramantieri L: In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol. 2012, 227 (3): 275-285.PubMed

101.

Wang YS, Wang YH, Xia HP, Zhou SW, Schmid-Bindert G, Zhou CC: MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev. 2012, 13 (1): 255-260.PubMed

102.

Wu Z, He B, He J, Mao X: Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate. 2013, 73 (6): 596-604.PubMed

103.

Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, Kung HF, Lai L, Jiang BH: MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One. 2011, 6 (4): e19139-PubMedCentralPubMed

104.

Dhar S, Hicks C, Levenson AS: Resveratrol and prostate cancer: promising role for microRNAs. Mol Nutr Food Res. 2011, 55 (8): 1219-1229.PubMed

105.

Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008, 322 (5908): 1695-1699.PubMedCentralPubMed

106.

Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH: Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One. 2012, 7 (3): e33729-PubMedCentralPubMed

107.

Coskun E, von der Heide EK, Schlee C, Kuhnl A, Gokbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD: The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. Leuk Res. 2011, 35 (2): 208-213.PubMed

108.

Ketola K, Kallioniemi O, Iljin K: Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells. PLoS One. 2012, 7 (12): e51470-PubMedCentralPubMed

109.

Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M: Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012, 18 (24): 6648-6657.PubMedCentralPubMed

110.

Thangapazham RL, Shaheduzzaman S, Kim KH, Passi N, Tadese A, Vahey M, Dobi A, Srivastava S, Maheshwari RK: Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome. Cancer Biol Ther. 2008, 7 (9): 1427-1435.PubMed

111.

Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Uren A: YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One. 2011, 6 (4): e19343-PubMedCentralPubMed

112.

Xu D, Lin TH, Li S, Da J, Wen XQ, Ding J, Chang C, Yeh S: Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer Lett. 2012, 316 (1): 11-22.PubMedCentralPubMed

113.

Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Matthews R, Grizzle WE, Rao VN, Bhat GK, Reddy ES: Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol. 2011, 39 (1): 111-119.PubMedCentralPubMed

114.

Bjorkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, Kallioniemi OP: Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer. 2008, 123 (12): 2774-2781.PubMed

115.

Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, Klein EA, Almasan A: PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One. 2013, 8 (4): e60408-PubMedCentralPubMed

116.

Shao L, Zhou Z, Cai Y, Castro P, Dakhov O, Shi P, Bai Y, Ji H, Shen W, Wang J: Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer. PLoS One. 2013, 8 (3): e58391-PubMedCentralPubMed

117.

Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R: Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci U S A. 2014, in press [PMID: 24591637]

118.

Farooqi AA, Rana A, Riaz AM, Khan A, Ali M, Javed S, Mukhtar S, Minhaj S, Rao JR, Rajpoot J, Amber R, Javed FA, Waqar Un N, Khanum R, Bhatti S: NutriTRAILomics in prostate cancer: time to have two strings to one's bow. Mol Biol Rep. 2012, 39 (4): 4909-4914.PubMed

119.

Farooqi AA, Butt G, Razzaq Z: Algae extracts and methyl jasmonate anti-cancer activities in prostate cancer: choreographers of 'the dance macabre'. Cancer Cell Int. 2012, 12 (1): 50-PubMedCentralPubMed

120.

Farooqi AA, Bhatti S, Ismail M: TRAIL and vitamins: opting for keys to castle of cancer proteome instead of open sesame. Cancer Cell Int. 2012, 12 (1): 22-PubMedCentralPubMed

121.

Wang D, Lu J, Tindall DJ: Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms. Cancer Lett. 2013, 335 (1): 136-144.PubMedCentralPubMed

122.

Taghiyev AF, Guseva NV, Sturm MT, Rokhlin OW, Cohen MB: Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer Biol Ther. 2005, 4 (4): 382-390.PubMed

123.

Kasman L, Lu P, Voelkel-Johnson C: The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. 2007, 14 (3): 327-334.PubMed

124.

Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, Kumar MV: SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. Int J Cancer. 2006, 119 (1): 221-228.PubMed

125.

Welch CM, Elliott H, Danuser G, Hahn KM: Imaging the coordination of multiple signalling activities in living cells. Nat Rev Mol Cell Biol. 2011, 12 (11): 749-756.PubMedCentralPubMed

Title: Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells
Authors: Ammad Ahmad Farooqi
Ming-Feng Hou
Chien-Chi Chen
Chun-Lin Wang
Hsueh-Wei Chang
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/1475-2867-14-34

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines

Glucose restriction decreases telomerase activity and enhances its inhibitor response on breast cancer cells: possible extra-telomerase role of BIBR 1532

SNP 1772 C > T of HIF-1α gene associates with breast cancer risk in a Taiwanese population

Rutin mediated targeting of signaling machinery in cancer cells

Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

Wnt5a promotes migration of human osteosarcoma cells by triggering a phosphatidylinositol-3 kinase/Akt signals

Keynote webinar | Spotlight on antibody–drug conjugates in cancer